|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DPY19L1 |
Gene summary for DPY19L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DPY19L1 | Gene ID | 23333 |
| Gene name | dpy-19 like C-mannosyltransferase 1 | |
| Gene Alias | DPY19L1 | |
| Cytomap | 7p14.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q2PZI1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23333 | DPY19L1 | HCC1_Meng | Human | Liver | HCC | 3.17e-11 | -3.87e-03 | 0.0246 |
| 23333 | DPY19L1 | HCC2_Meng | Human | Liver | HCC | 3.19e-22 | 1.99e-01 | 0.0107 |
| 23333 | DPY19L1 | HCC2 | Human | Liver | HCC | 6.60e-03 | 1.34e+00 | 0.5341 |
| 23333 | DPY19L1 | S014 | Human | Liver | HCC | 1.40e-02 | 2.97e-01 | 0.2254 |
| 23333 | DPY19L1 | S015 | Human | Liver | HCC | 1.38e-09 | 5.14e-01 | 0.2375 |
| 23333 | DPY19L1 | S027 | Human | Liver | HCC | 1.64e-02 | 3.88e-01 | 0.2446 |
| 23333 | DPY19L1 | S028 | Human | Liver | HCC | 1.88e-09 | 4.70e-01 | 0.2503 |
| 23333 | DPY19L1 | S029 | Human | Liver | HCC | 2.38e-10 | 4.99e-01 | 0.2581 |
| 23333 | DPY19L1 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.46e-02 | 2.33e-01 | 0.3371 |
| 23333 | DPY19L1 | RNA-P3T-P3T-1 | Human | Lung | IAC | 2.20e-02 | 3.88e-01 | 0.1829 |
| 23333 | DPY19L1 | RNA-P3T-P3T-2 | Human | Lung | IAC | 1.65e-02 | 3.35e-01 | 0.1835 |
| 23333 | DPY19L1 | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.39e-03 | 4.11e-01 | 0.1859 |
| 23333 | DPY19L1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.28e-21 | 7.26e-01 | -0.0166 |
| 23333 | DPY19L1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.86e-30 | 7.83e-01 | -0.0132 |
| 23333 | DPY19L1 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.98e-28 | 7.14e-01 | -0.013 |
| 23333 | DPY19L1 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.97e-19 | 6.71e-01 | -0.0121 |
| 23333 | DPY19L1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 6.02e-03 | 4.49e-01 | -0.0876 |
| 23333 | DPY19L1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 1.48e-03 | 4.62e-01 | -0.0809 |
| 23333 | DPY19L1 | C04 | Human | Oral cavity | OSCC | 9.12e-04 | 2.52e-01 | 0.2633 |
| 23333 | DPY19L1 | C21 | Human | Oral cavity | OSCC | 2.27e-04 | 1.95e-01 | 0.2678 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:00064863 | Lung | AIS | protein glycosylation | 35/1849 | 226/18723 | 4.93e-03 | 4.27e-02 | 35 |
| GO:00434133 | Lung | AIS | macromolecule glycosylation | 35/1849 | 226/18723 | 4.93e-03 | 4.27e-02 | 35 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
| GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
| GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DPY19L1 | SNV | Missense_Mutation | c.791C>A | p.Thr264Asn | p.T264N | Q2PZI1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
| DPY19L1 | SNV | Missense_Mutation | c.1862N>A | p.Arg621Lys | p.R621K | Q2PZI1 | protein_coding | tolerated(0.32) | possibly_damaging(0.76) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
| DPY19L1 | SNV | Missense_Mutation | c.1771N>G | p.Met591Val | p.M591V | Q2PZI1 | protein_coding | tolerated(0.38) | probably_damaging(0.949) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DPY19L1 | SNV | Missense_Mutation | novel | c.100N>A | p.His34Asn | p.H34N | Q2PZI1 | protein_coding | tolerated(0.17) | probably_damaging(0.988) | TCGA-D8-A1XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DPY19L1 | SNV | Missense_Mutation | c.157N>T | p.Thr53Ser | p.T53S | Q2PZI1 | protein_coding | tolerated(0.41) | benign(0.109) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| DPY19L1 | insertion | In_Frame_Ins | novel | c.361_362insGACAGGAAGGAAAAATTAAGTGCTTAGAACTTC | p.Thr121delinsArgGlnGluGlyLysIleLysCysLeuGluLeuPro | p.T121delinsRQEGKIKCLELP | Q2PZI1 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DPY19L1 | SNV | Missense_Mutation | rs200053924 | c.1951N>A | p.Val651Met | p.V651M | Q2PZI1 | protein_coding | tolerated(0.22) | possibly_damaging(0.897) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| DPY19L1 | SNV | Missense_Mutation | novel | c.740C>T | p.Ser247Phe | p.S247F | Q2PZI1 | protein_coding | tolerated(0.13) | probably_damaging(0.996) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| DPY19L1 | SNV | Missense_Mutation | novel | c.541N>A | p.Leu181Ile | p.L181I | Q2PZI1 | protein_coding | tolerated(0.12) | probably_damaging(0.992) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DPY19L1 | SNV | Missense_Mutation | c.124N>A | p.Phe42Ile | p.F42I | Q2PZI1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |